

India

ADD (no change)

Consensus ratings*: Buy 31	Hold 9 Sell 3
Current price:	Rs723
Target price:	Rs840
Previous target:	Rs750
Up/downside:	16.2%
InCred Research / Consensus:	9.2%
Reuters:	MRCO.NS
Bloomberg:	MRCO IN
Market cap:	US\$10,710m
	Rs938,717m
Average daily turnover:	US\$17.3m
	Rs1513.1m
Current shares o/s:	1,291.2m
Free float:	40.6%
*Source: Bloomberg	

Key changes in this note

- > Raise the target price to Rs840 from Rs750.
- Introduce FY28F estimates.



		Source: Bloomberg		
Price performance	1M	ЗМ	12M	
Absolute (%)	(0.7)	3.7	9.2	
Relative (%)	2.2	3.4	6.1	

Major shareholders	% held
Promoter	59.4
LIC	2.7
Blackrock	2.3

Marico Ltd

Healthy delivery despite a weak environment

- Domestic sales/volume grew 27%/9% yoy in 1QFY26. Rural markets continued to outperform urban markets. IBD grew 12% yoy on a reported basis.
- Margins are expected to remain range bound as Marico chases volume growth. Copra prices are expected to remain elevated in the near term.
- Initiatives to revive growth in general trade & scale new businesses are in the right direction. Retain ADD with a higher TP of Rs840 (50x Jun 2027F EPS).

Posts healthy volume growth despite sharp price hikes

Marico posted 23.3% sales growth on a consolidated basis in 1QFY26 led by a 20.9% yoy sales growth in the standalone business, with a 9% volume growth (vs. our estimate of 8.5%). Consolidated gross margin contracted by 533bp yoy to 46.9% led by a 730bp yoy contraction in standalone gross margin to 39.1%, largely dragged by a sharp rise in copra prices. The Parachute range grew by 31% yoy in value terms, with a 1% volume dip (1% growth when adjusted for grammage changes). The value-added hair oils (VAHO) category posted a 13% yoy sales growth, after multiple quarters, owing to sluggishness at the category level. Mid & premium formats fared well. Edible oils posted a 28% yoy sales growth, with mid-single digit volume growth. The foods business posted a 20% yoy sales growth while the premium personal care segment sustained its robust growth momentum. International business (IBD) was up 19%/12% on a constant currency/INR basis respectively, led by a 17% growth in Bangladesh and a 42% yoy growth in the MENA region while Vietnam/South Africa grew 1%/flat yoy, respectively.

Measures to improve distribution and mix should support growth

Marico's digital portfolio exited 1Q with a Rs8.5bn+ ARR, on track to top Rs10bn in FY26F and is targeting a Rs20bn revenue potential across Beardo, Just Herbs, Plix & True Elements. Beardo is nearing double-digit EBITDA margin. Marico will leverage its offline scale to deepen penetration. Marico retains its low double-digit sales growth guidance for FY26F, with 2HFY26F likely to be volume-led as cumulative pricing (+60% taken in Parachute range) normalizes. Margin recovery is likely from 2QFY26F as copra prices have eased from their peak in Jul 2025. The food portfolio continued to benefit from structural gross margin expansion and now stands at 5x FY20 revenue, which Marico wants to touch 8x by FY27F, led by a 25%+ CAGR in core categories (oats, honey, muesli), that will be driven by GT expansion, especially in categories like muesli & honey, where modern trade's share is higher. Food & premium personal care segments now account for 22% of India sales.

Outlook stays positive; retain ADD rating with a higher TP of Rs840

Marico's focus on driving volume growth, addressing GT channel issues, and scaling new verticals are in the right direction. Despite near-term gross margin headwinds from copra inflation, calibrated pricing and improvement in sales mix should aid EBITDA margin improvement to the 20% range. Retain ADD rating with a new target price of Rs840 (50x Jun 2027F EPS). Downside risk: Sustained weakness in demand from urban markets.

Financial Summary	Mar-24A	Mar-25A	Mar-26F	Mar-27F	Mar-28F
Revenue (Rsm)	96,530	108,310	123,008	137,824	153,834
Operating EBITDA (Rsm)	20,260	21,390	23,598	28,117	30,460
Net Profit (Rsm)	13,390	16,290	16,875	20,953	23,500
Core EPS (Rs)	10.4	12.6	13.1	16.2	18.2
Core EPS Growth	15.6%	21.7%	3.6%	24.2%	12.2%
FD Core P/E (x)	69.68	57.28	55.29	44.53	39.70
DPS (Rs)	5.5	7.9	8.9	10.9	12.1
Dividend Yield	0.89%	1.28%	1.45%	1.76%	1.95%
EV/EBITDA (x)	45.82	42.93	38.85	32.65	30.14
P/FCFE (x)	77.88	65.75	273.13	52.98	52.98
Net Gearing	(19.6%)	(41.5%)	(32.5%)	(29.1%)	(29.1%)
P/BV (x)	24.35	23.47	19.59	20.00	16.53
ROE	35.1%	41.7%	38.6%	44.4%	45.6%
% Change In Core EPS Estimates			(0.14%)	5.37%	
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Research Analyst(s)



Rohan KALLE

T (91) 22 4161 1561 E rohan.kalle@incredresearch.com

Nishant BAGRECHA


T (91) 22 4161 1564


E nishant.bagrecha@incredresearch.com



Healthy delivery despite a weak environment

Y/E Mar (Rs. m)	1QFY25	4QFY25	1QFY26	YoY (%)	QoQ (%)	FY24	FY25	Gr (%)
Revenue	26,430	27,300	32,590	23.3	19.4	96,530	1,08,310	12.2
Expenditure	20,170	22,720	26,040	29.1	14.6	76,270	86,920	14.0
Consumption of Raw Materials	12,620	14,040	17,300	37.1	23.2	47,480	53,880	13.5
as % of sales	47.7	51.4	53.1			49.2	49.7	
Employee Costs	2,030	2,080	2,200	8.4	5.8	7,430	8,310	11.8
as % of sales	7.7	7.6	6.8			7.7	7.7	
Other Expenditure	5,520	6,600	6,540	18.5	-0.9	21,360	24,730	15.8
as % of sales	20.9	24.2	20.1			22.1	22.8	
EBITDA	6,260	4,580	6,550	4.6	43.0	20,260	21,390	5.6
Depreciation	410	520	450	9.8	-13.5	1,580	1,780	12.7
EBIT	5,850	4,060	6,100	4.3	50.2	18,680	19,610	5.0
Other Income	370	470	560	51.4	19.1	1,420	2,080	46.5
Interest	170	120	100	-41.2	-16.7	730	530	-27.4
PBT	6,050	4,410	6,560	8.4	48.8	19,370	21,160	9.2
Total Tax	1,310	960	1,430	9.2	49.0	4,350	4,580	5.3
PAT	4,740	3,450	5,130	8.2	48.7	15,020	16,580	10.4
(Profit)/Loss From JVs/Ass./MI	100	20	90	-10.0	350.0	210	290	38.1
APAT after Minority Interest (MI)	4,640	3,430	5,040	8.6	46.9	14,810	16,290	10.0
Extraordinary Items	0	0	0	NA	NA	0	0	NA
Reported PAT	4,640	3,430	5,040	8.6	46.9	14,810	16,290	10.0
EPS	3.6	2.7	3.9	8.6	46.9	11.5	12.6	10.0
Margins (%)	1QFY25	4QFY25	1QFY26	YoY (bp)	QoQ (bp)	FY24	FY25	(bp
Gross margin	52.3	48.6	46.9	-530	-170	50.8	50.3	-60
EBITDA	23.7	16.8	20.1	-360	330	21.0	19.7	-120
EBIT	22.1	14.9	18.7	-340	380	19.4	18.1	-120
EBT	22.9	16.2	20.1	-280	400	20.1	19.5	-50
PAT	17.9	12.6	15.7	-220	310	15.6	15.3	-30
Effective Tax Rate	21.7	21.8	21.8	10	0	22.5	21.6	-80
















Figure 6: Food portfolio scaling well; gross margin improvement is expected to continue Foods portfolio at 5x of FY20 scale On course to become ~8x of FY20 scale in FY27 Foods Revenues (in ₹ cr.) ~8x ~5x FY25 FY20 FY24 FY27E Foods poised for 25%+ CAGR driven by scale up of existing franchises and product innovations


















Figure 11: Market leadership across categories					
Franchise	~MS%	Rank			
Coconut Oil Franchise	63%	1 st			
O Parachute Rigids within Coconut Oil	53%	1 st			
Saffola Oats	41%	1 st			
OValue Added Hair Oils	29%	1 st			
O Post wash Leave-on Serums	47%	1 st			
Hair Gels/Waxes/Creams	53%	1 st			
SOL	URCE: INCRED RESEARCH,	COMPANY REPORTS			

Figure 12: Our revised earnings estima	tes						
V/E May (Days)		FY26F			FY27F		
Y/E Mar (Rs. m)	Earlier	Revised	% Change	Earlier	Revised	% Change	Introduced
Net Sales	1,16,892	1,23,008	5.2	1,28,687	1,37,824	7.1	1,53,834
EBITDA	23,645	23,598	-0.2	26,781	28,117	5.0	30,460
EBITDA Margin (%)	20.2	19.2	-100bp	20.8	20.4	-40bp	19.8
Net Income (Before Exceptional Items)	16,951	16,875	-0.5	19,903	20,953	5.3	23,500
EPS	13.1	13.1	-0.5	15.4	16.2	5.3	18.2
					SOURCE: INCREI	D RESEARCH, CO	MPANY REPORTS







40


30

20

10

0

BY THE NUMBERS



(Rs mn)	Mar-24A	Mar-25A	Mar-26F	Mar-27F	Mar-28F
Total Net Revenues	96,530	108,310	123,008	137,824	153,834
Gross Profit	49,050	54,430	60,153	68,129	76,220
Operating EBITDA	20,260	21,390	23,598	28,117	30,460
Depreciation And Amortisation	(1,580)	(1,780)	(2,254)	(2,729)	(3,203)
Operating EBIT	18,680	19,610	21,344	25,388	27,257
Financial Income/(Expense)	(730)	1,550	(522)	556	1,982
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)					
Profit Before Tax (pre-EI)	17,950	21,160	20,822	25,943	29,239
Exceptional Items					
Pre-tax Profit	17,950	21,160	20,822	25,943	29,239
Taxation	(4,350)	(4,580)	(3,747)	(4,791)	(5,539)
Exceptional Income - post-tax					
Profit After Tax	13,600	16,580	17,075	21,153	23,700
Minority Interests	(210)	(290)	(200)	(200)	(200)
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	13,390	16,290	16,875	20,953	23,500
Recurring Net Profit	13,390	16,290	16,875	20,953	23,500
Fully Diluted Recurring Net Profit	13,390	16,290	16,875	20,953	23,500

Cash Flow					
(Rs mn)	Mar-24A	Mar-25A	Mar-26F	Mar-27F	Mar-28F
EBITDA	20,260	21,390	23,598	28,117	30,460
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(1,520)	7,790	6,757	(2,830)	(7,152)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense					
Other Operating Cashflow	1,420	2,080	198	1,296	2,722
Net Interest (Paid)/Received	(730)	(530)	(720)	(740)	(740)
Tax Paid	(4,350)	(4,580)	(3,747)	(4,791)	(5,539)
Cashflow From Operations	15,080	26,150	26,086	21,051	19,751
Capex	(5,800)	(4,170)	2,118	(4,700)	(4,700)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments					
Other Investing Cashflow	2,700	(7,790)	(3,000)	(3,000)	(3,000)
Cash Flow From Investing	(3,100)	(11,960)	(4,412)	(7,700)	(7,700)
Debt Raised/(repaid)					
Proceeds From Issue Of Shares					
Shares Repurchased					
Dividends Paid	(12,290)	(4,530)	(13,484)	(16,436)	(18,203)
Preferred Dividends					
Other Financing Cashflow					
Cash Flow From Financing	(12,290)	(4,530)	(13,484)	(16,436)	(18,203)
Total Cash Generated	(310)	9,660	(10,243)	1,872	1,872
Free Cashflow To Equity	11,980	14,190	3,416	17,611	17,611
Free Cashflow To Firm	12,710	14,720	4,136	18,351	18,351

SOURCE: INCRED RESEARCH, COMPANY REPORTS

BY THE NUMBERS...cont'd

Balance Sheet					
(Rs mn)	Mar-24A	Mar-25A	Mar-26F	Mar-27F	Mar-28F
Total Cash And Equivalents	12,020	21,520	22,917	21,789	21,789
Total Debtors	10,690	12,710	20,788	26,176	32,425
Inventories	13,360	12,350	22,331	20,867	23,290
Total Other Current Assets	6,350	6,100	5,968	6,716	7,520
Total Current Assets	42,420	52,680	69,348	71,597	71,597
Fixed Assets	16,070	18,370	20,736	22,707	24,204
Total Investments	5,670	2,300	2,300	2,300	2,300
Intangible Assets	9,370	9,460	5,708	5,708	5,708
Total Other Non-Current Assets	(2,110)	(1,910)	(1,910)	(1,910)	(1,910)
Total Non-current Assets	29,000	28,220	27,810	29,852	29,852
Short-term Debt	3,830	3,830	3,830	3,830	3,830
Current Portion of Long-Term Debt					
Total Creditors	15,810	13,630	38,378	40,204	42,504
Other Current Liabilities					
Total Current Liabilities	19,640	17,460	42,208	44,034	46,334
Total Long-term Debt			20	20	20
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities					
Total Non-current Liabilities			20	20	20
Total Provisions	80	220	157	173	196
Total Liabilities	19,720	17,680	29,277	30,898	30,898
Shareholders Equity	38,320	39,750	47,641	46,657	56,454
Minority Interests	3,370	2,910	2,910	2,910	2,910
Total Equity	41,690	42,660	50,551	49,567	59,364

Key Ratios					
	Mar-24A	Mar-25A	Mar-26F	Mar-27F	Mar-28F
Revenue Growth	(1.1%)	12.2%	13.6%	12.0%	11.6%
Operating EBITDA Growth	11.9%	5.6%	10.3%	19.1%	8.3%
Operating EBITDA Margin	21.0%	19.7%	19.2%	20.4%	19.8%
Net Cash Per Share (Rs)	6.35	13.71	14.78	13.91	13.91
BVPS (Rs)	29.71	30.81	36.93	36.17	43.76
Gross Interest Cover	25.59	37.00	29.64	34.31	36.83
Effective Tax Rate	24.2%	21.6%	18.0%	18.5%	18.9%
Net Dividend Payout Ratio	62.2%	73.0%	79.9%	78.4%	77.5%
Accounts Receivables Days	39.40	39.43	49.70	62.19	69.52
Inventory Days	98.44	87.08	100.70	113.12	103.83
Accounts Payables Days	116.58	99.72	151.01	205.77	194.48
ROIC (%)	49.3%	45.1%	50.5%	52.1%	52.1%
ROCE (%)	41.6%	42.6%	39.9%	38.2%	38.2%
Return On Average Assets	20.9%	19.7%	17.6%	17.7%	17.7%

SOURCE: INCRED RESEARCH, COMPANY REPORTS



DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd. (formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. While every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which is believed to be accurate and complete and obtained through reliable public or other non-confidential sources at the time made (information barriers and other arrangements may be established, where necessary, to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.


IRSPL may have issued other reports (based on technical analysis, event specific, short-term views, etc.) that are inconsistent with and reach a different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

Research Analyst or his/her relative(s) or InCred Research Services Private Limited or our associate may have any financial interest in the subject company.

Research Analyst or his/her relatives or InCred Research Services Limited or our associates may have actual or beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the Research Report.

Research Analyst or his/her relative or InCred Research Services Private Limited or our associate entities may have any other material conflict of interest at the time of publication of the Research Report.





In the past 12 months, IRSPL or any of its associates may have:

- a) Received any compensation/other benefits from the subject company,
- b) Managed or co-managed public offering of securities for the subject company,
- c) Received compensation for investment banking or merchant banking or brokerage services from the subject company,
- d) Received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company

We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.

Research Analyst may have served as director, officer, or employee in the subject company.

We or our research analyst may engage in market-making activity of the subject company.

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his
 or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and
 autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based on any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm
 performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in this report and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.

Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

InCred Research Services Private Limited

Research Analyst SEBI Registration Number: INH000011024

Registered Office: Unit No 1203, 12th Floor, B Wing, The Capital, C-70, G Block, BKC, Bandra (E), Mumbai – 400051

Phone: +91-22-6844-6100

Corporate Office: 05th floor, Laxmi Towers, Plot No. C-25, G Block, Bandra - Kurla Complex, Bandra (East), Mumbai - 400051

Phone: +91-22-4161-1500

Name of the Compliance Officer: Mr. Yogesh Kadam

Email ID: compliance@incredresearch.com, Phone No: +91-22-41611539 For any queries or grievances, you may contact the Grievance Officer.

Name of the Grievance Officer: Mr. Rajarshi Maitra

Phone no. +91-022-41611546

Email ID: rajarshi.maitra@incredresearch.com

CIN: U74999MH2016PTC287535



Recommendation Framework

Stock Ratings Definition:

Add The stock's total return is expected to exceed 10% over the next 12 months.

Hold The stock's total return is expected to be between 0% and positive 10% over the next 12 months.

Reduce The stock's total return is expected to fall below 0% or more over the next 12 months.

The total expected return of a stock is defined as the sum of the: (i) percentage difference between the target price and the current price and (ii) the forward net dividend yields of the stock. Stock price targets have an investment horizon of 12 months.

Sector Ratings Definition:

Overweight An Overweight rating means stocks in the sector have, on a market cap-weighted basis, a positive absolute recommendation.

Neutral A Neutral rating means stocks in the sector have, on a market cap-weighted basis, a neutral absolute recommendation.

Underweight An Underweight rating means stocks in the sector have, on a market cap-weighted basis, a negative absolute recommendation.

Country Ratings Definition

Overweight An Overweight rating means investors should be positioned with an above-market weight in this country relative to benchmark.

Neutral A Neutral rating means investors should be positioned with a neutral weight in this country relative to benchmark.

Underweight An Underweight rating means investors should be positioned with a below-market weight in this country relative to benchmark.